摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(5E)-8-[4-(2-butoxyethoxy)phenyl]-1-(2-methylpropyl)-N-[4-[(S)-(3-propylimidazol-4-yl)methylsulfinyl]phenyl]-3,4-dihydro-2H-1-benzazocine-5-carboxamide;methanesulfonic acid | 497223-28-6

中文名称
——
中文别名
——
英文名称
(5E)-8-[4-(2-butoxyethoxy)phenyl]-1-(2-methylpropyl)-N-[4-[(S)-(3-propylimidazol-4-yl)methylsulfinyl]phenyl]-3,4-dihydro-2H-1-benzazocine-5-carboxamide;methanesulfonic acid
英文别名
Cenicriviroc mesylate
(5E)-8-[4-(2-butoxyethoxy)phenyl]-1-(2-methylpropyl)-N-[4-[(S)-(3-propylimidazol-4-yl)methylsulfinyl]phenyl]-3,4-dihydro-2H-1-benzazocine-5-carboxamide;methanesulfonic acid化学式
CAS
497223-28-6
化学式
C42H56N4O7S2
mdl
——
分子量
793.1
InChiKey
IXPBPUPDRDCRSY-YLZLUMLXSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    145.5-147.5 °C(Solv: 2-butanone (78-93-3))
  • 溶解度:
    DMSO:100.0(最大浓度 mg/mL);126.1(最大浓度 mM)

计算性质

  • 辛醇/水分配系数(LogP):
    8.25
  • 重原子数:
    55
  • 可旋转键数:
    17
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    168
  • 氢给体数:
    2
  • 氢受体数:
    10

安全信息

  • 储存条件:
    | 2-8℃ |

制备方法与用途

Cenicriviroc 是一种兼具两种作用机制的双重拮抗剂。

文献信息

  • BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF
    申请人:TOBIRA THERAPEUTICS, INC.
    公开号:US20160008326A1
    公开(公告)日:2016-01-14
    The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula: wherein, R 1 is a 5- to 6-membered ring group which may be substituted; X 1 is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X 2 is a bivalent group of 1 to 4 atom; Z 1 is a bivalent cyclic ring group or the like; Z 2 is a bond or the like; and R 2 is an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.
    本发明提供了一种具有CCR拮抗活性的新环化合物,特别是CCR5拮抗活性,以及其用途。本发明的化合物由以下公式表示:其中,R1是一个可能被取代的5至6成员环基团;X1是键或类似物;环A是一个可能被取代的5至6成员环基团;环B是一个可能被取代的8至10成员环基团;X2是1至4原子的二价基团;Z1是二价环状基团或类似物;Z2是键或类似物;R2是氨基、可能被取代的含氮杂环基团或类似物,或其盐。
  • PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC
    申请人:Tobira Therapeutics, Inc.
    公开号:US20170362207A1
    公开(公告)日:2017-12-21
    The disclosure includes high purity compounds having CCR5 and/or CCR2 antagonism, or salts thereof, high purity intermediates thereto and processes for synthesizing the same.
    该文件涉及高纯度化合物,具有CCR5和/或CCR2拮抗作用,或其盐,以及制备这些化合物的高纯度中间体和合成过程。
  • [EN] BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF<br/>[FR] COMPOSE BICYCLIQUE, PRODUCTION ET UTILISATION CORRESPONDANTES
    申请人:TAKEDA CHEMICAL INDUSTRIES LTD
    公开号:WO2003014105A1
    公开(公告)日:2003-02-20
    The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula (I) wherein: R1 is a 5- to 6-membered ring group which may be substituted; X1 is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X2 is a bivalent group of 1 to 4 atoms; Z1 is a bivalent cyclic ring group or the like; Z2 is a bond or the like; and R2 is an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.
    本发明提供了一种具有CCR拮抗剂活性,特别是CCR5拮抗剂活性的新的环状化合物及其用途。本发明的化合物由式(I)表示,其中:R1是可取代的5-至6-成员环基团;X1是键或类似物;环A是可取代的5-至6-成员环基团;环B是可取代的8-至10-成员环基团;X2是1至4个原子的双价基团;Z1是双价的环状环基团或类似物;Z2是键或类似物;R2是氨基、可能被取代的含氮杂环基团或类似物,或其盐。
  • Bicyclic compound, production and use thereof
    申请人:——
    公开号:US20040259876A1
    公开(公告)日:2004-12-23
    The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula: 1 wherein, R 1 is a 5- to 6-membered ring group which may be substituted; X 1 is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X 2 is a bivalent group of 1 to 4 atoms; Z 1 is a bivalent cyclic ring group or the like; Z 2 is a bond or the like; and R 2 is an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.
    本发明提供了一种具有CCR拮抗剂活性,特别是CCR5拮抗剂活性的新型环状化合物以及其用途。本发明的化合物由下式表示:1其中,R1是一个可被取代的5-至6-成员环基团;X1是一个键或类似物;环A是一个可被取代的5-至6-成员环基团;环B是一个可被取代的8-至10-成员环基团;X2是1至4个原子的双价基团;Z1是一个双价环状基团或类似物;Z2是一个键或类似物;R2是氨基、含氮杂环基团(可被取代)或类似物的盐。
  • Bicyclic Compound, Production and Use Thereof
    申请人:Shiraishi Mitsuru
    公开号:US20090030032A1
    公开(公告)日:2009-01-29
    The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula: wherein, R 1 is a 5- to 6-membered ring group which may be substituted; X 1 is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X 2 is a bivalent group of 1 to 4 atoms; Z 1 is a bivalent cyclic ring group or the like; Z 2 is a bond or the like; and R 2 is an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.
    本发明提供了一种具有CCR拮抗剂活性的新环状化合物,特别是CCR5拮抗剂活性,以及其用途。本发明的化合物由下式表示:其中,R1是一个5-至6-成员环基团,可以被取代;X1是一个键或类似物;环A是一个5-至6-成员环基团,可以被取代;环B是一个8-至10-成员环基团,可以被取代;X2是1至4个原子的二价基团;Z1是二价环状环基团或类似物;Z2是一个键或类似物;R2是氨基、含氮杂环基团(可以被取代)或类似物的盐。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐